Monitoring the response to Nintedanib treatment in a mouse model of lung fibrosis using longitudinal X-ray based lung function measurement
Authors Khan A, Markus AM, Svetlove A, Hülsmann S, Alves F, Dullin C Journal Research Square Citation Research Square, 12 April 2023, preprint. Abstract Background: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive, incurable, and debilitating fibrotic disease. Nintedanib – an oral tyrosine kinase inhibitor – significantly slows the IPF
